Drugs / BJ-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04294576 | Dec 2019 → Apr 2024 | — | BJ Bioscience, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BJ-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04294576 ↗ |
| Modality | Protein / enzyme biologic | “BJ-001, a human IL-15 fusion protein” NCT04294576 ↗ |
| Route | Subcutaneous | “administered via subcutaneous injections” NCT04294576 ↗ |